

Cytosorbents Corp  
Form 8-K  
May 21, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 16, 2012

**CYTOSORBENTS CORPORATION**

(Exact name of registrant as specified in its charter)

**Nevada**                      **000-51038 98-0373793**

(State or other jurisdiction (Commission (IRS Employer  
of incorporation)              File Number) Identification No.)

**7 Deer Park Drive, Suite K**

**Monmouth Junction, New Jersey 08852**

Edgar Filing: Cytosorbents Corp - Form 8-K

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(732) 329-8885**

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written  
communications  
..pursuant to Rule  
425 under the  
Securities Act (17  
CFR 230.425)

Soliciting material  
pursuant to Rule  
14a-12 under the  
Exchange Act (17  
CFR 240.14a-12)

Pre-commencement  
communications  
..pursuant to Rule  
14d-2(b) under the  
Exchange Act (17  
CFR 240.14d-2(b))

Pre-commencement  
communications  
..pursuant to Rule  
13e-4(c) under the  
Exchange Act (17  
CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

CytoSorbents Corporation (the “Company”) responded to a number of questions from shareholders on May 16, 2012 and prepared a list of Frequently Asked Questions (“FAQs”) along with responses to these and other common inquiries. The FAQs was posted on the Company’s website on May 20, 2012. A copy of the FAQs is attached herewith as Exhibit 99.1.

The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

Item 9.01 Financial Statements and Exhibits

Exhibits

99.1\* List of Frequently Asked Questions posted on the CytoSorbents Corporation website.

\* The List of Frequently Asked Questions is furnished and not filed pursuant to Instruction B.2 of Form 8-K.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 21, 2012 CytoSorbents  
Corporation

By: /s/ David Lamadrid  
Name: David  
Lamadrid  
Title: Chief  
Financial Officer